Claria Medical announced today that it received FDA de novo authorization for its Claria system for minimally invasive hysterectomies.
Fertility declines as women get older for many reasons, such as a drop in egg quality, decreased follicle numbers and hardening of ovarian tissues.
Researchers have solved a long-standing mystery of how abnormal chromosomes drive cancer, identifying 81 new genes involved in aggressive breast cancer.
Carea, the pregnancy and postnatal wellbeing app, has launched its new Contraction Timer designed to support women during labour through a combination of contraction tracking, labour pattern analysis and wellbeing tools.
Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool – the first in Europe and the United Kingdom to detect breast cancer using magnetic resonance imaging – which automatically identifies suspected lesions on breast MRI.
One current viral health trend on TikTok claims that a combination of two over-the-counter drugs can help manage symptoms during those few days each month. Despite the lack of clinical trials to back up this seemingly odd blend of accessible medications, there is some biological reasoning behind this one.
Michigan State University researchers have identified how ovarian cancer cells become resistant to chemotherapy and discovered a protein that, when blocked, can restore the drug’s effectiveness.
This authorisation will expand the B-Right AI platform’s use to Europe, as BrightHeart continues to roll the technology out across the US.
Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients.
A tiny silk sticker that visibly shows vital health signals, read by an AI system, could change how we care for the tiniest patients